IL2 and neoplasm: Combination treatment studies involving tumor-specific cytotoxic T lymphocytes (CTLs), PEGylated IL-2, and activated NKIL−12 revealed that only groups containing activated NKIL−12 demonstrated statistically significant prolonged survival over mock constructs, untreated, and CTL alone controls in B16-OVA tumor bearing mouse models.